HHS Policy Shift May Boost Patient Advocate Roles in Rare Disease Drug Trials

A recent policy shift by the U.S. Department of Health and Human Services (HHS) may increase the involvement of patient advocates in clinical trials, particularly in the development of drugs for rare and serious diseases. Bruce Leuchter, CEO of Neurvati, highlighted the critical contributions patient advocates make to trial design, site selection, and regulatory strategies during a discussion on this evolving landscape.

Leuchter emphasized that patient advocates play an essential role in ensuring that clinical trials address the unique needs of patients with rare or severe conditions. Their input can help refine trial protocols to improve accessibility and relevance for participants while also influencing decisions about where trials are conducted to maximize enrollment opportunities. Additionally, their perspectives often inform regulatory approaches that align with patient priorities. This policy adjustment by HHS could formalize and expand these contributions, potentially reshaping how drug development processes incorporate patient-centered insights moving forward.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 23, 2025

Author

Mark Chiang